Techno Medica Co., Ltd. AI Stock Analysis
Want to see JP:6678 full AI Analyst Report?
Techno Medica Co., Ltd. (6678) AI Stock Analysis
Techno Medica Co., Ltd.
(TSE/TYO:6678)
The overall score of 78 is primarily driven by the company's exceptional financial health and attractive valuation. The fortress balance sheet with zero debt and a high dividend yield of 5.91% are the most significant strengths. A low P/E ratio of 12.49 further enhances the investment case. These positive factors are balanced by a moderate technical trend and the key risk of declining profit margins, which prevents a higher score. The company's ability to reverse margin compression will be critical for future performance.
Techno Medica Co., Ltd. (6678) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 14.37B
- Dividend Yield
- 5.91%
- Average Volume (3M)
- 12.11K
- Price to Earnings (P/E)
- 12.5
- Beta (1Y)
- 0.52
- Revenue Growth
- 17.11%
- EPS Growth
- 23.02%
- Country
- Japan
- Employees
- 239
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Techno Medica Co., Ltd. Business Overview & Revenue Model
Company Description
Techno Medica Co., Ltd. is a Japanese company that specializes in the entire lifecycle of in-vitro diagnostic analyzers, covering their research, development, manufacturing, distribution, and international trade. Their product portfolio includes auto...
How the Company Makes Money
Techno Medica primarily makes money by selling in-vitro diagnostic equipment (analyzers and related laboratory systems) to medical institutions and testing laboratories, and by generating recurring revenue from consumables and reagents used with its...
Techno Medica Co., Ltd. Financial Statement Overview
Summary
Techno Medica exhibits a robust financial profile, anchored by a pristine, debt-free balance sheet (Score 90) and consistent, high-quality cash flow generation (Score 80). Strong revenue growth of 16.3% is a key positive, though this is partially offset by margin compression, with net margin falling to a six-year low, as reflected in the Income Statement Score of 68. The overall financial health is strong, but declining profitability is a notable headwind.
Income Statement
68PositiveBalance Sheet
90Very PositiveCash Flow
80Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.59B | 11.24B | 9.91B | 10.28B | 9.37B | 9.70B |
| Gross Profit | 5.44B | 5.24B | 4.88B | 5.10B | 4.59B | 4.78B |
| EBITDA | 1.96B | 1.76B | 1.40B | 1.95B | 1.76B | 1.96B |
| Net Income | 1.19B | 1.07B | 1.00B | 1.35B | 1.15B | 1.28B |
Balance Sheet | ||||||
| Total Assets | 15.49B | 17.97B | 17.94B | 17.43B | 19.44B | 18.51B |
| Cash, Cash Equivalents and Short-Term Investments | 8.44B | 8.98B | 9.06B | 8.59B | 11.75B | 11.52B |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.27B | 3.56B | 3.55B | 3.62B | 3.06B | 2.86B |
| Stockholders Equity | 13.22B | 14.41B | 14.39B | 13.82B | 16.39B | 15.65B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.07B | 952.67M | 1.10B | 748.50M | 2.00B |
| Operating Cash Flow | 0 | 1.10B | 977.53M | 1.14B | 887.24M | 2.06B |
| Investing Cash Flow | 0 | -39.76M | -32.34M | -100.72M | -155.37M | 2.49B |
| Financing Cash Flow | 0 | -1.15B | -470.16M | -4.21B | -505.09M | -598.64M |
Techno Medica Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6678, the sentiment is Positive. The current price of 2146.00 is above the 20-day moving average (MA) of 2126.10, above the 50-day MA of 2064.16, and below the 200-day MA of 2150.18, indicating a bullish trend. The MACD of 34.02 indicates Negative momentum. The RSI at 61.94 is Neutral, neither overbought nor oversold. The STOCH value of 49.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:6678.
Techno Medica Co., Ltd. Peers Comparison
Overall Rating
JP:667878Outperform
JP:684963Neutral
JP:652361Neutral
JP:796359Neutral
JP:454950Neutral
JP:760045Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | JPY 18.61B | 12.49 | ― | 5.91% | 17.11% | 23.02% | |
| 63Neutral | JPY 253.13B | 20.90 | ― | 2.07% | -0.18% | -33.38% | |
| 61Neutral | JPY 160.43B | 11.13 | 8.71% | 3.33% | 2.74% | 145.33% | |
| 59Neutral | JPY 8.14B | 9.84 | ― | 3.02% | 8.56% | 7.14% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | JPY 73.85B | 39.86 | ― | 2.59% | 3.92% | -52.01% | |
| 45Neutral | JPY 8.08B | -5.20 | ― | 5.54% | -8.68% | -75.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:6678 | Techno Medica Co., Ltd. | 2146.00 | 271.73 | 14.50% | |
| JP:6523 | PHC Holdings Corp. | 1300.00 | 374.19 | 40.42% | |
| JP:4549 | Eiken Chemical Co., Ltd. | 2240.00 | 37.76 | 1.71% | |
| JP:6849 | Nihon Kohden Corporation | 1550.00 | 20.56 | 1.34% | |
| JP:7600 | Japan Medical Dynamic Marketing, Inc. | 306.00 | -165.73 | -35.13% | |
| JP:7963 | Koken Ltd. | 1658.00 | -143.49 | -7.97% |
Techno Medica Co., Ltd. Corporate Events
Techno Medica Reports Strong First-Half Earnings Growth
Techno Medica Co., Ltd., a Tokyo-listed company, reported non-consolidated net sales of ¥4.453 billion for the six months ended September 30, 2026, up 8.5% year on year, while operating profit rose 75.7% to ¥468 million and net profit increased 58.2%...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
